These results constitute useful information for the development of YRA-1909 as a new herbal medicine for the treatment of rheumatoid arthritis, based on the evaluation of the pharmacokinetic properties of its main components (i.e., CGA, CCGA, and NCGA) and their active metabolites (CA, CA-3-G, and CA-4-G). This evidence concerns the gene CA3 and rheumatoid arthritis.